ABSTRACT
BACKGROUND: In the months of October and November 2021, there was throughout Italy and in our specific case in the area of Lucca and Versilia, a disturbing increase of SARS-CoV-2 infections and cases of Respiratory Syncytial Virus (RSV) in new-borns. The aim of this paper is to compare the cases of RSV infection diagnosed in recent years to the cases recorded during the SARS-CoV-2 pandemic to November 2022. MATERIALS AND METHODS: The study consisted of evaluating the results of requests for RSV diagnosis from 2015 to November 2022, using molecular biology techniques. RESULTS: The data obtained show that the number of cases of RSV infection in children during the winter season had a constant trend from 2015 to 2019. From November 2020 to February 2021 there were no cases of RSV respiratory infections. Starting from September 2021, on the other hand, there was a resumption of cases of RSV infections in conjunction with an increase in the number of children affected by COVID-19. From January 2022, after a peak in cases of SARS-CoV-2 infection, there has been a decrease in RSV infections. From September 2022 to November 2022, there was no increase of cases of RSV infections in new-borns but on the contrary, there was a trend in respiratory infections comparable to the pre-pandemic period. CONCLUSION: The data that emerged from the study conducted, show the onset of an outbreak of RSV in new-borns. This incidence is linked to the implementation of rigorous non-pharmacological public health interventions in 2020, aimed at combating COVID-19 infection. The use of the molecular panel made it possible to identifying the responsible agent and highlighting the most suitable clinical and therapeutic path.
Subject(s)
COVID-19 , Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Humans , Child , Pandemics , COVID-19/epidemiology , SARS-CoV-2 , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Syncytial Virus Infections/epidemiology , Respiratory Tract Infections/epidemiology , COVID-19 TestingSubject(s)
Immunosuppressive Agents/adverse effects , Kidney Transplantation/immunology , Leishmaniasis, Mucocutaneous/pathology , Tongue Diseases/pathology , Tongue Diseases/parasitology , Adult , Antibodies, Protozoan/blood , Humans , Kidney Transplantation/adverse effects , Leishmaniasis, Mucocutaneous/drug therapy , Male , Middle Aged , Tongue Diseases/drug therapyABSTRACT
Pyoderma gangrenosum (PG) is a rare, noninfectious, neutrophilic dermatosis of unknown origin that is associated with systemic diseases in 50% of cases. The authors present a case of a 54-year-old man patient with refractory to conventional treatment PG associated with ulcerative colitis and psoriasis, which showed a successful response to treatment with infliximab, a chimeric monoclonal antibody that inhibits tumor necrosis factor alpha (TNF-α). This case report shows the frequent difficulty in the therapeutic approach of PG, especially if associated with underlying disease, and necessity to apply new agents, such as a novel application of the TNF-α inhibitors, in relationship to the recent pathogenic knowledge.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Pyoderma Gangrenosum/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Colitis, Ulcerative/complications , Humans , Infliximab , Male , Middle Aged , Psoriasis/complications , Pyoderma Gangrenosum/complications , Pyoderma Gangrenosum/pathologyABSTRACT
Pseudoxanthoma elasticum (PXE) is a genetic multisystem disorder characterized by ectopic mineralization of connective tissues with primary manifestations in the skin, retina and cardiovascular system, and a phenotypic spectrum highly variable.This article presents the case of a 46-year-old male patient with sporadic late-onset PXE, without severe systemic complications.
